Protocol Details
Hematologic Malignancy Biology Study
This study is currently recruiting participants.
Summary
Number |
04-C-0102 |
Sponsoring Institute |
National Cancer Institute (NCI) |
Recruitment Detail |
Type: Enrolling by Invitation
Gender: Male & Female
Min Age: 1 Years
Max Age: 120 Years |
Referral Letter Required |
Yes |
Population Exclusion(s) |
Neonates |
Keywords |
Acute Lymphoblastic Leukemia;
Acute Lymphocytic Leukemia;
Pediatric Blood Disorders;
Hodgkins and non-Hodgkins lymphoma;
MDS;
Natural History |
Recruitment Keyword(s) |
None |
Condition(s) |
Acute Lymphoblastic Leukemia;
Myelodysplastic Syndrome (MDS);
Non-Hodgkins Lymphoma;
Acute Myelogenous Leukemia;
Hodgkins Lymphoma |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
None |
Supporting Site |
National Cancer Institute |
This study will collect tumor samples from people with cancers of the blood, bone marrow, or lymph glands for laboratory study of the biology of these conditions. Such studies contribute to a better understanding of cancer biology and to the development of new treatments. Planned studies include:
- Examination of individual cancer cells and to search for differences compared to other types of cancer and normal cells
- Examination of the chromosomes and genes in cancer cells and to search for differences compared to other types of cancer and normal cells
- Development of sensitive methods to detect small amounts of cancer that remain after treatment
- Search for new cancer proteins that might serve as targets for treatment
- Investigation of methods to develop cancer vaccines.
Patients from >= 1 to 75 years of age with acute lymphocytic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, juvenile myelomonocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, and other hematologic malignancies may be eligible for this study.
Blood or bone marrow samples will be collected when sampling is required for the patient's medical care. Cells from some individuals will be grown in test tubes, establishing cell lines or in animals, establishing xenograft models. (A xenograft is transplantation of cells of one species to another species.)
Eligibility
INCLUSION CRITERIA
Confirmed pathological diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following:
Acute Lymphocytic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Chronic Myelogenous Leukemia (CML)
Juvenile Myelomonocytic Leukemia (JMML, J-CML)
Non-Hodgkin's Lymphoma (NHL)
Hodgkin's Disease
Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care.
Age: >= 1 years.
Prior therapy: no restrictions
Subject, parent/guardian, legally authorized representative (LAR), or durable power of attorney must be able to give informed consent and sign the informed consent document.
EXCLUSION CRITERIA
None
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT00923442